Eli Lilly (LLY) officer (EVP, CS&PO & Pres. LRL) reported a Code G transaction of 179 shares of common stock on 11/10/2025 at a reported price of $0.
Following the transaction, the officer beneficially owned 137,481.112 shares directly. Indirect holdings were reported as 72,359 shares by a trust, 547 shares by a spouse, and 2,710 shares by a spouse’s SLAT, subject to a standard pecuniary interest disclaimer.
The filing notes a 200‑share correction to reconcile these holdings with a submission filed on August 12, 2025.
Lilly Endowment Inc. filed a Form 144 indicating a proposed sale of 300,000 shares of Eli Lilly and Company common stock, with an aggregate market value of $277,311,000. The filing lists Fidelity Capital Markets as broker, an approximate sale date of 11/10/2025, and the securities exchange as NYSE, NASDAQ.
The shares to be sold were originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust (donor acquisition date 01/21/1937). The notice also reports recent sales by Lilly Endowment Inc. over the past three months, including 300,000 shares on 11/03/2025 for $266,648,940 and 351,015 shares on 10/01/2025 for $284,653,451.48.
Lilly Endowment Inc., a reporting person for Eli Lilly and Company (LLY), reported multiple open‑market sales of common stock on 11/05/2025, totaling 40,432 shares across eight transactions coded “S.”
The trades executed at weighted‑average prices with ranges disclosed from $947.18 to $955.41. Following these transactions, the reporting person beneficially owned 93,711,978 shares with direct ownership.
Eli Lilly & Co (LLY): A reporting person identified as a director and 10% owner reported open‑market sales of common stock on 11/05/2025 across 30 separate transactions. The trades were executed at weighted‑average prices disclosed by tranche, with individual price ranges noted in the footnotes.
Following these sales, the reporting person directly beneficially owned 93,752,410 shares. The footnotes show sale price ranges spanning from $910.90 to $947.06 per share across the listed tranches. The remark states this is the first of two Forms 4 filed the same day, covering transactions #1–#30 of 38 total.
Lilly Endowment Inc., a director of Eli Lilly (LLY), reported selling 526 shares of common stock on 11/04/2025 with transaction code S. The sale was executed at a weighted average price of $910.719.
The shares were sold in multiple trades at prices ranging from $910.59 to $911.00. After this transaction, the reporting person beneficially owned 93,931,452 shares, held directly.
Lilly Endowment Inc., a director of Eli Lilly (LLY), reported open‑market sales totaling 300,000 shares of common stock on 11/03/2025.
The trades were executed in multiple tranches at weighted average prices with reported ranges from $877.00 to $901.295 per share, as detailed in footnotes. Following these transactions, the reporting person beneficially owned 93,931,978 shares directly.
Lilly Endowment Inc. filed a Form 144 notice to sell up to 220,000 shares of Eli Lilly and Company (LLY) common stock, reflecting an aggregate market value of $197,236,600. The filing lists J.P. Morgan Securities LLC as broker and an approximate sale date of 11/04/2025.
Shares outstanding were 945,383,757. The Endowment reports prior sales in the last three months, including 351,015 shares on 10/01/2025 for $284,653,451.48 and 300,000 shares on 11/03/2025 for $266,648,940. The securities trace back to a historical gift acquisition from the J.K. Lilly Sr. Trust.
Eli Lilly (LLY): insider transaction reported. On 10/31/2025, the reporting person executed open-market sales of common stock across multiple tranches totaling 301,342 shares. The weighted average prices for each tranche reflected ranges from $862.00 to $869.9057, as disclosed in footnotes. Following these transactions, the reporting person beneficially owned 94,231,978 shares, held directly.
The sales were recorded as code “S” and reported with weighted average prices for each tranche; detailed per-trade pricing within the stated ranges is available upon request, according to the disclosure. The filing was signed “/s/ Diane M. Stenson, Vice President and Treasurer, on behalf of Lilly Endowment Inc.”
Lilly Endowment Inc. filed a Form 144 notice to sell 300,000 shares of Eli Lilly and Company common stock. The filing lists an aggregate market value of $258,858,000, with Fidelity Capital Markets as broker and an approximate sale date of 11/03/2025. The shares are listed on NYSE and NASDAQ.
Shares outstanding were 945,383,757; this is a baseline figure, not the amount being offered. In the past three months, the seller reported multiple open-market sales, including 351,015 shares on 10/01/2025 for $284,653,451.48 and 301,342 shares on 10/31/2025 for $260,164,971.74.
Lilly Endowment, Inc. filed Amendment No. 43 to Schedule 13G reporting beneficial ownership of 95,492,993 shares of Eli Lilly (LLY) common stock, representing 10.1% of the class. The ownership is reported as of September 30, 2025, and the percentage is based on 946,456,759 shares outstanding as of August 4, 2025 per the issuer’s Form 10‑Q.
The Endowment has sole voting power and sole dispositive power over 95,492,993 shares, with no shared voting or dispositive power. The filer is an Indiana not‑for‑profit organization and private foundation.